ACRIVON THERAPEUTICS INC

ACRVNASDAQ

🏆 #4154 by market capEarnings Nov 11US Equity

$2.08▲ $0.05 (+2.46%)

After hours · at close

🔔

Track ACRV

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.5%

7d▼ 3.0%

14d▲ 14.3%

30d▲ 1.0%

ytd▼ 13.9%

1y▲ 13.7%

🏦Market Cap

$89M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $2.06 – $2.10
52-Week Range: $1.27 – $3.56
Volume: $2.71B
Avg Volume: $2.81B
Shares Outstanding: 42.8M
Next Earnings: Nov 30, 2026

Fundamentals Snapshot

Annual Revenue: $12M
Last Q Revenue: $3M
P/E Ratio: -1.1
P/S Ratio: 0.0x
EPS (TTM): $-1.77
Dividend Yield: 0.00%
Dilution (1yr): +0.7%

Why Investors Own ACRV

✓High-growth profile — revenue up -3.1% YoY with expanding US Equity exposure.
✓Healthy economics — 66% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ACRIVON THERAPEUTICS INC

ACRV

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$84M▼ −5.7% YoY

Free Cash Flow

−$65M▼ −4.5% YoY

Shares Outstanding

38.5M▲ +0.7% YoY

Net Cash

$39M▲ +$3M YoY

StockOtter · stockotter.space

About ACRIVON THERAPEUTICS INC

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

🦦